Roche (ROG) Given a CHF 300 Price Target at Goldman Sachs

Goldman Sachs set a CHF 300 price target on Roche (VTX:ROG) in a research note released on Tuesday morning. The firm currently has a buy rating on the healthcare company’s stock.

Other research analysts also recently issued reports about the stock. Liberum Capital set a CHF 279 price target on shares of Roche and gave the stock a buy rating in a report on Wednesday, November 22nd. Baader Bank set a CHF 256 price target on shares of Roche and gave the stock a buy rating in a report on Tuesday, November 21st. Sanford C. Bernstein set a CHF 262 price target on shares of Roche and gave the stock a buy rating in a report on Friday, December 1st. Bank of America set a CHF 275 price target on shares of Roche and gave the stock a buy rating in a report on Wednesday, December 6th. Finally, JPMorgan Chase & Co. set a CHF 290 price target on shares of Roche and gave the stock a buy rating in a report on Friday, December 8th. Four analysts have rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the company’s stock. Roche currently has a consensus rating of Hold and an average target price of CHF 254.80.

How to Become a New Pot Stock Millionaire

Roche (VTX:ROG) opened at CHF 219.60 on Tuesday. The stock has a market cap of $191,160.00 and a price-to-earnings ratio of 21.87. Roche has a 1-year low of CHF 214.30 and a 1-year high of CHF 273.

TRADEMARK VIOLATION NOTICE: “Roche (ROG) Given a CHF 300 Price Target at Goldman Sachs” was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3294392/roche-rog-given-a-chf-300-price-target-at-goldman-sachs.html.

Roche Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Analyst Recommendations for Roche (VTX:ROG)

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Smart Sand  Expected to Post Earnings of $0.08 Per Share
Smart Sand Expected to Post Earnings of $0.08 Per Share
JetPay  Getting Favorable News Coverage, Accern Reports
JetPay Getting Favorable News Coverage, Accern Reports
Glen Burnie Bancorp  Receives News Sentiment Rating of -0.08
Glen Burnie Bancorp Receives News Sentiment Rating of -0.08
MKS Instruments  Releases Q2 Earnings Guidance
MKS Instruments Releases Q2 Earnings Guidance
Vipshop  versus Qurate Retail Group  Critical Contrast
Vipshop versus Qurate Retail Group Critical Contrast
Reviewing Chunghwa Telecom  and Cellcom
Reviewing Chunghwa Telecom and Cellcom


© 2006-2018 Ticker Report. Google+.